Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year. This growth was largely driven by $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. The drug recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%.
The strong performance of TONMYA is a key indicator of its market acceptance and the company's commercial execution. Currently, TONMYA has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to about 145 million lives when a managed Medicare agreement takes effect on January 1, 2027, which could further boost sales and patient access.
Beyond commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These initiatives highlight Tonix's commitment to addressing high unmet medical needs in central nervous system (CNS) and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides stability as the company continues to invest in its commercial and clinical programs.
The impressive growth in TONMYA prescriptions and revenue underscores the potential of this first new fibromyalgia treatment in over 15 years. With expanding coverage and a robust pipeline, Tonix is positioning itself for sustained growth in the biotech sector. The company's focus on CNS and immunology, with products like Zembrace SymTouch and Tosymra for acute migraine, further diversifies its portfolio.
Investors and industry observers will be watching closely as Tonix progresses its late-stage trials and commercial expansion. The company's ability to capitalize on TONMYA's early success while advancing other promising candidates will be critical to its long-term trajectory.
